PhIII prostate cancer failure forces deep job cuts at Active Biotech

Just 6 weeks after seeing disappointing data from its Phase III study of tasquinimod for prostate cancer, Sweden's Active Biotech is laying off 47 staffers, leaving only 9 employees at the company. The drug delayed disease progression but failed to achieve an improvement in overall survival, forcing Ipsen out of their collaboration. Release